

SHEET

OF 2

Complete if known

Application Number: 09/734,801


Filing Date: December 12, 2000

First Named Inventor: Roland Carlsson, et. al.

Group Art Unit: 1637

Examiner Name: Suryaprabha Chunduru


Attorney Docket Number: EricPotter



UNITED STATES PATENT DOCUMENTS							
EXAMINER'S CITE PATENT NUMBER INITIALS NO.			ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR			
	A1	6,143,527	11-07-2000	Catherine J. Pachuk, et. al.			

	FOREIGN PATENT DOCUMENTS								
EXAMINER'S • INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT				
Spe 1	B1	WO 98/01581	PCT	01-15-1998	Recombinant Biocatalysis, Inc.				
7	B2	WO 99/23236	PCT	05-14-1999	Diversa Corporation				
-	B3	WO 01/96551	PCT	12-20-2001	Diversa Corporation				
/	B4	WO 02/29032	PCT	04-11-2002	Diversa Corporation				
	B5	WO 00/46344	PCT	08-10-2000	Diversa Corporation				
	B 6	WO 00/53744	, PCT	09-14-2000	Diversa Corporation				
٧	B7	WO 00/77262	PCT	12-21-2000	Diversa Corporation				
	B8	WO 00/58517	PCT	10-05-2000	Diversa Corporation				
1	B9	WO 97/07205	PCT	02-27-1997	Novo Nordisk A/S				
-	B10	WO 97/07206	PCT	02-27-1997	Novo Nordisk A/S				
	B11	WO 98/41623	PCT	09-24-1998	Novo Nordisk A/S				
	B12	WO 98/41622	PCT	09-24-1998	Novo Nordisk A/S				
	B13	WO 98/28416	PCT	07-02-1998	Novo Nordisk A/S				
1	B14	WO 00/72013	PCT	11-30-2000	The Penn State Research Foundation				
1	B15	WO 01/75158	PCT	10-11-2001	The <u>Penn State Research</u> Foundation				
	B16	WO 96/05803	PCT	02-29-1996	Quest International B.V.				
	B17	WO 01/34835	PCT	05-17-2001	Max-Planck Gesellschaft zur Förderung der Wissenschaften E.V., et. al.				
4	B18	WO 99/58661	PCT	11-18-1999	Diatech Pty. Ltd.				

EXAMINER'S SIGNATURE	Brobha Chemdum	DATE CONSIDERED	3/28/05



Complete if known

Application Number: 09/734,801

Filing Date: December 12, 2000

First Named Inventor: Roland Carlsson, et. al.

Group Art Unit: 1637

Examiner Name: Suryaprabha Chunduru

SHEET 2 OF 2


Attorney Docket Number: EricPotter

SPO.	B19	WO 02/16606	PCT	02-28-2002	Biomethodes
e fil	B20	WO 00/09679	PCT	02-24-2000	Proteus (S.A.)
\$ P /	B21	WO 00/34512	PCT	06-15-2000	Proteus (S.A.)

OTHER PRIOR ART - NON-PATENT DOCUMENTS						
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				
. 8k						


JUN 0 4 2003
TECH CENTER 1600/2900

EXAMINER'S	2		DATE		1 /	,	
SIGNATURE	Brobbe	Chemdum	CONSIDERED	3	281	δζ	
				1 _	, ,		



UNITED STATES PATENT DOCUMENTS							
EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR			
Ca	A1	4,888,286	12-19-1989	Crea			
37	A2	5,023,171	06-11-1991	Ho et al.			
	A3	5,252,479	10-12-1993	Srivastava			
	A4	5,270,170	12-14-1993	Schatz et al.			
	A5	5,338,665	08-16-1994	Schatz et al.			
	A6	5,491,074	02-13-1996	Aldwin et al.			
	A7	5,498,530	03-12-1996	Schatz et al.			
	A8	5,512,463	04-30-1996	Stemmer			
	A9	5,514,568	05-07-1996	Stemmer			
	A10	5,521,291	05-28-1996	Curiel et al.			
	A11	5,573,907	11-12-1996	Carrino et al.			
	A12	5,605,793	02-25-1997	Stemmer			
	A13	5,712,089	01-27-1998	Borrebaeck et al.			
	A14	5,723,323	03-03-1998	Kauffman et al.			
	A15	5,733,731	03-31-1998	Schatz et al.			
	A16	5,733,753	03-31-1998	Jørgensen			
	A17	5,763,192	06-09-1998	Kauffman et al.			
	A18	5,798,208	08-25-1998	Crea			
	A19	5,811,238	09-22-1998	Stemmer et al.			
	A20	5,814,476	09-29-1998	Kauffman et al.			
	A21	5,817,483	10-06-1998	Kauffman et al.			
1	A22	5,824,514	10-20-1998	Kauffman et al.			

EXAMINER'S SIGNATURE	Busha C	hemdun	DATE CONSIDERED	3:128/05



2

SHEET

OF 9

Application Number: 09/734,801

Filing Date: December 12, 2000

First Named Inventor: Carlsson, et al.

Group Art Unit: 1637


Examiner Name: Chunduru, Suryaprabha

Attorney Docket Number: 0046-P02386US0

Complete if known

Spe	A23	5,830,650	11-03-1998	Crea
	A24	5,830,696	11-03-1998	Short
	A25	5,830,721	11-03-1998	Stemmer et al.
	A26	5,834,252	11-10-1998	Stemmer et al.
	A27	5,837,458	11-17-1998	Minshull et al.
	A28	5,858,657	01-12-1999	Winter et al.
	A29	5,858,725	01-12-1999	Crowe et al.
	A30	5,871,907	02-16-1999	Winter et al.
	A31	5,925,544	07-20-1999	Jørgensen
•	A32	5,928,905	07-27-1999	Stemmer et al.
-	A33	5,939,250	08-17-1999	Short
•	A34	5,965,408	10-12-1999	Short
	A35	5,969,108	10-19-1999	McCafferty et al.
	A36	5,976,862	11-02-1999	Kauffman et al.
	A37	6,096,548	08-01-2000	Stemmer
	A38	6,117,679	09-12-2000	Stemmer
	A39	6,132,970	10-17-2000	Stemmer
	A40	6,143,527	11-07-2000	Pachuk et al.
	A41	6,153,410	11-28-2000	Amold et al.
	A42	6,156,511	12-05-2000	Schatz et al.
	A43	6,159,687	12-12-2000	Vind
	A44	6,159,688	12-12-2000	Borchert, et al.
J)	A45	6,159,690	12-12-2000	Borrebaeck et al.

EXAMINER'S	0 11		DATE	2/2005
SIGNATURE	Bribne	(hendum	CONSIDERED	3 18 9




	FOREIGN PATENT DOCUMENTS								
EXAMIN	NER'S	CITE	DOCUMENT	COUNTRY OR	DATE OF	FIRST NAMED INVENTOR OR			
INITI	ALS	NO.	NUMBER	REGION	PUBLICATION	APPLICANT			
					MM-DD-YYYY				
800	2	B1	WO 86/05803	PCT	10-09-1986	Ballivet, Kauffman			
		B2	EP 0 368 684 A	EP	05-16-1990	Medical Research Council			
	ν	В3	EP 0 415 731 A	EP	03-06-1991	The Wellcome Foundation			
						Limited			
		B4	EP 0 456 304 A	EP	11-13-1991	Eastman Kodak Company			
		B 5	EP 0 590 689 A	EP	04-06-1994	Ballivet, Kauffman			
		B6	WO 90/07936	PCT	07-26-1990	Chiron Corporation			
		B7	WO 90/14430	PCT	11-29-1990	Scripps Clinic and Research			
						Foundation			
		B8	WO 92/01047	PCT	01-23-1992	Cambridge Antibody			
						Technology Limited			
		B9	WO 92/15702	PCT	09-17-1992	Bradbury			
		B10	WO 93/07282	PCT	04-15-1993	Boehringer Ingelheim			
						International GMBH			
		B11	WO 93/08278	PCT	04-29-1993	Affymax Technologies N.V.			
		B12	WO 93/12257	PCT	06-24-1993	Hybridtech Incorporated			
		B13	WO 94/12632	PCT	06-09-1994	University College London			
		B14	WO 94/28173	PCT	12-08-1994	Affymax Technologies N.V.			
		B15	WO 95/22625	PCT	08-24-1995	Affymax Technologies N.V.			
	\ \ \ \	B16	WO 96/05803	PCT	02-29-1996	Quest International B.V.			
		B17	WO 96/17056	PCT	06-06-1996	Institut Pasteur			
	1.	B18	WO 96/40750	PCT	12-19-1996	Glaxo Group Limited			
	j	B19	WO 96/40987	PCT	12-19-1996	Affymax Technologies N.V.			
	7	B20	WO 97/07205	PCT	02-27-1997	Novo Nordisk A/S			

EXAMINER'S SIGNATURE	Bubha	Chundum	DATE CONSIDERED	3/28/05
SIGNATURE			OUNDENED	

	Complete if known
U 3C53 30	Application Number: 09/734,801
	Filing Date: December 12, 2000
DISCLOSURE O STATEMENT	Eirst Named Inventor: Carlsson, et al.
	Group Art Unit: 1637
	Examiner Name: Chunduru, Suryaprabha
SHEET 4 OF 9	Attorney Docket Number: 0046-P02386US0

	1		DOT	02-27-1997	Novo Nordisk A/S
SPC	B21	WO 97/07206	PCT		
	B22	WO 97/08320	PCT	03-06-1997	Morphosysgesellschaft für
<u> </u>					Proteinoptimierung MBH
	B23	WO 97/20078	PCT	06-05-1997	Affymax Technologies N.V.
	B24	WO 97/35957	PCT	10-02-1997	Maxygen, Inc.
ı	B25	WO 97/35966	PCT	10-02-1997	Maxygen, Inc.
	B26	WO 98/01581	PCT	01-15-1998	Recombinant Biocatalysis, Inc
	B27	WO 98/05765	PCT	02-12-1998	Novo Nordisk A/S
- (B28	WO 98/13485	PCT	04-02-1998	Maxygen, Inc.
	B29	WQ 98/13487	PCT ,	04-02-1998	Maxygen, Inc.
	B30	WO 98/25965	PCT	06-18-1998	Glaxo Group Limited
_	B31	WO 98/27230	PCT	06-25-1998	Maxygen, Inc.
	B32	WO 98/28416	PCT	07-02-1998	Novo Nordisk A/S
	B33	WO 98/31837	PCT	07-23-1998	Maxygen, Inc.
	B34	WO 98/32845	PCT	07-30-1998	Bioinvent International AB
	B35	WO 98/41622	PCT	09-24-1998	Novo Nordisk A/S
_	B36	WO 98/41623	PCT	09-24-1998	Novo Nordisk A/S
-	B37	WO 98/58080	PCT	12-23-1998	Bioinvent International AB
	B38	WO 99/21979	PCT	05-06-1999	Maxygen, Inc.
		WO 99/23107	PCT	05-14-1999	Maxygen, Incorporated
	B40	WO 99/23236	PCT	05-14-1999	Diversa Corporation
	B41	WO 99/33965	PCT	07-08-1999	Diatech Pty. Ltd.
	B42	WO 99/41368	PCT	08-19-1999	Maxygen, Inc.
	B43	WO 99/41369	PCT	08-19-1999	Maxygen, Inc.
	B44	WO 99/41383	PCT	08-19-1999	Maxygen, Inc.
	B45	WO 99/41402	PCT .	08-19-1999	Maxygen, Inc.
	B46	WO 99/45110	PCT	09-10-1999	Diatech Pty. Ltd.
- \}	B47	WO 99/57128	PCT	11-11-1999	Maxygen, Inc.

			
EXAMINER'S	Robba Chunduru	DATE	1 3/12/105
SIGNATURE	Bubba Chimania	CONSIDERED	5(%
I OIGITA OILE	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		



8PC	B48	WO 99/58661	PCT	11-18-1999	Diatech Pty. Ltd.
	B49	WO 99/65927	PCT	12-23-1999	Maxygen, Inc.
	B50	WO 00/04190	PCT	01-27-2000	Maxygen, Inc.
	B51	WO 00/09679	PCT	02-24-2000	Proteus
1	B52	WO 00/09727	PCT	02-24-2000	Maxygen, Inc.
	B53	WO 00/12680	PCT	03-09-2000	Maxygen, Inc.
	B54	WO 00/18906	PCT	04-06-2000	Maxygen, Inc.
	B55	WO 00/20573	PCT	04-13-2000	Maxygen, Inc.
	B56	WO 00/28008	PCT	05-18-2000	Maxygen, Inc.
- -	B57	WO 00/28017	PCT	05-18-2000	Maxygen, Inc.
	B58	WO 00/28018	PCT	05-18-2000	Maxygen, Inc.
	B59	WO 00/34512	PCT	06-15-2000	Proteus
	B60	WO 00/42559	PCT	07-20-2000	Maxygen, Inc.
1	B61	WO 00/42560	PCT	07-20-2000	Maxygen, Inc.
	B62	WO 00/42561	PCT	07-20-2000	Maxygen, Inc.
	B63	WO 00/46344	PCT	08-10-2000	Diversa Corporation
- -	B64	WO 00/52155	PCT	09-08-2000	Maxygen, Inc.
-+-	B65	WO 00/53744	PCT	09-14-2000	Diversa Corporation
١ ,	B66	WO 00/58517	PCT	10-05-2000	Diversa Corporation
	B67	WO 00/61731	PCT	10-19-2000	Maxygen, Inc.
	B68	WO 00/61740	PCT	10-19-2000	Maxygen, Inc.
,	B69	WO 00/72013	PCT	11-30-2000	The Penn State Research Foundation
	B70	WO 00/73433	PCT	12-07-2000	Novo Nordisk A/S
	B71	2000-308490 A	Japan	11-07-2001	Maxygen, Inc.
,	B72	10-66576	Japan Publication	03-10-1998	Novo Nordisk Aktie Selsxat
1	B73	2813314	France	03-01-2002	Biomethodes

EXAMINER'S	Rakha	Chemdura	DATE	2/20/05
SIGNATURE	prova	Charten	CONSIDERED	8(-8/-3

	Complete if known
,	Application Number: 09/734,801
INFORMATION () () () () () ()	Filing Date: December 12, 2000
DISCLUSURE "	First Named Inventor: Carlsson, et al.
STATEMENT STATEMENT	Group Art Unit: 1637
PATEMEN	Examiner Name: Chunduru, Suryaprabha
SHEET 6 OF 9	Attorney Docket Number: 0046-P02386US0


		OTHER PRIOR ART - NON-PATENT DOCUMENTS
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
8p	C1	Berger, et al., "Expanding the Potential of Restriction Endonucleases: Use of Hapaxoterministic Enzymes", Anal. Biochem. 222:1-8, (1994)
	C2	Cadwell, et al., "Randomization of Genes by PCR Mutagenesis", PCT Methods Appl., 2:28-33, (1992)
	C3	Cadwell, et al., "Mutagenic PCR", PCT Methods Appl., 3:S136-140, (1994)
	C4	Casson & Manser, "Evaluation of Loss and Change of Specificity Resulting from Random Mutagenesis of an Antibody V _H Region", J. Immunol. 155: 5647-5654 (1995)
	C5	Chalfie, et al., "Green Florescent Protein as a Marker for Gene Expression", Science 263: 802-805 (1994)
	C6	Chen, et al., "Tuning the activity of an enzyme for unusual environments: Sequential random mutagenesis of subtilisin E for catalysis in dimethylformamide", Proc. Natl. Acad. Sci. USA 90: 5618-5622 (1993)
	C7	Crameri, et al., "DNA shuffling of a family of genes from diverse species accelerates directed evolution", Nature, 391: 288-291 (1998)
	C8	Deng, et al., "Simultaneous randomization of antibody CDRs by a synthetic ligase chain reaction strategy", Nucl. Acid Res. 21: 4418-4419, (1993)
	C9	Engberg, et al., "Phage-Display Libraries of Murine and Human Antibody Fab Fragments", Molecular Biotechnolgoy 6: 287-310, (1996)
	C10	Giver, et al., "Directed evolution of a thermostable esterase", Proc. Natl. Acad. Sci. USA 95: 12809-12813, (1998)
	C11	Gram, et al., "In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library", Proc. Natl. Acad. Sci. USA 89: 3576-3580, (1992)
1	C12	Hansson, et al., "Evolution of Differential Substrate Specificities in Mu Class Glutathione Transferases Probed by DNA Shuffling", J. Mol. Biol. 287: 265-276, (1999)

EXAMINER'S	Radda	alinadina.	DATE	3/20/00
SIGNATURE	Exercise	Chundim	CONSIDERED	0/28(03

	Complete if known
	Application Number: 09/734,801
CTATERIENT 9	Filing Date: December 12, 2000
	First Named Inventor: Carlsson, et al.
	Group Art Unit: 1637
	Examiner Name: Chunduru, Suryaprabha
SHEET 7 OF 9 PATEN	Attorney Docket Number: 0046-P02386US0

	C13	Henke & Bornscheuer, "Directed Evolution of an Esterase from Pseudomonas fluorescens.
C.OL.		Random Mutagenesis by Error-Prone PCR or a Mutator Strain and Identification of Mutants
8/1		Showing Enhanced Enantioselectivity by a Resorufin-Based Fluorescence Assay", Biol. Chem.,
		380: 1029-1033, (1999)
	C14	Ho, et al., "Site-directed mutagenesis by overlap extension using the polymerase chain
		reaction", Gene 77: 51-59, (1989)
	C15	Hoogenboom, et al., "By-passing Immunisation: Human Antibodies from Synthetic Repertoires
		of Germline V _H Gene Segments Rearranged in Vitro", J. Mol. Biol. 227: 381-388, (1992)
	C16	Horton, et al., "Engineering hybrid genes without the use of restriction enzymes: gene splicing
		by overlap extension", Gene, 77: 61-68, (1989)
	C17	Jansen, et al., "Disruption of phase during PCR amplification and cloning of heterozygous target
		sequences", NAR, 18: 5153-5156, (1990)
	C18	Kikuchi, et al., "Novel family shuffling methods for the in vitro evolution of enzymes", Gene 236:
		159-167, (1999)
	C19	Kobayashi, et al., "Analysis of Assembly of Synthetic Antibody Fragments: Expression of
		Functional scFv with Predefined Specificity", Biotechniques, 23: 500-503, (1997)
	C20	Kwekkeboom, et al., "CD40 plays an essential role in the activation of human B cells by murine
		EL485 cells", Immunol. 79: 439-444, (1993)
	C21	Lewin, "Genes IV", page 272, Oxford University Press, (1990)
	C22	Lewis & Crowe, "Immunoglobulin complementary-determining region grafting by recombinant
		polymerase chain reaction to generate humanised monoclonal antibodies", Gene 101: 297-302
		(1991)
	C23	Liu, et al., "Replacement and deletion mutations in the catalytic domain and belt region of
		Aspergillus awamori glucoamylase to enhance thermostability*, Protein Eng. 13: 655-659
		(2000)
	C24	Luqmani & Lymboura, "Subtraction Hybridization Cloning of RNA Amplified From Different Cell
1		Populations Microdissected From Cryostat Tissue Sections", Anal. Biochem., 222: 102-109,
Ψ Ψ		(1994)

Signature	EXAMINER'S SIGNATURE	Buldra Chemduru	DATE CONSIDERED	3/28/05
-----------	-------------------------	-----------------	--------------------	---------



OF 9

SHEET

	Complete if known
Application Number	: 09/734,801

Filing Date: December 12, 2000

First Named Inventor: Carlsson, et al.

Group Art Unit: 1637

Examiner Name: Chunduru, Suryaprabha

Attorney Docket Number: 0046-P02386US0

	C25	May, et al., "Inverting enantioselectivity by directed evolution of hydantoinase for improved		
800		production of L-methionine", Nat. Biotechnol. 18: 317-320, (2000)		
	C26	Meyerhans, et al., "DNA recombination during PCR", Nucl. Acid Res., 18: 1687-91, (1990)		
	C27	Moore, et al., "Directed evolution of a para-nitrobenzyl esterase for aqueous-organic solvents",		
		Nature Biotechnology, 14: 458-467 (1996)		
	C28	Orlandi, et al., "Cloning immunoglobulin variable domains for expression by the polymerase		
	1	chain reaction", Proc. Natl. Acad. Sci. USA, 86: 3833-3837 (1989)		
	C29	Paabo, et al., "Ancient DNA and the Polymerase Chain Reaction", J. Biol. Chem., 264: 9709-		
1		9712, (1989)		
	C30	Paabo, et al., "DNA Damage Promotes Jumping between Templates during Enzymatic		
		Amplification", J. Biol. Chem., 265: 4718-4721, (1990)		
	C31	Prickett, et al., "A Calcium-Dependent Antibody for Identification and Purification of		
		Recombinant Proteins", BioTechniques, 7: 580-589, (1989)		
	C32	Roberts, et al., "Generation of an antibody with enhanced affinity and specificity for its antigen		
		by protein engineering", Nature, 328: 731-734, (1987)		
	C33	Schmidt-Dannert, et al., "Molecular breeding of carotenoid biosynthetic pathways", Nat.		
		Biotechnol., 18: 750-753, (2000)		
	C34	Shyur, et al., "Site-directed Mutagenesis of Residues at Subunit Interfaces of Procine Fructose		
		1,6-bisphosphatase", J. Biol. Chem., 271: 3005-3010, (1996)		
	C35	Söderlind, et al., "Domain libraries: Synthetic diversity for de novo design of antibody V-		
		regions*, Gene, 160: 269-272, (1995)		
	C36	Song, et al., "Simultaneous Enhancement of Thermostability and Catalytic Activity of		
	1	Phospholipase A, by Evolutionary Molecular Engineering", Appl. Environ. Microbiol. 66: 890		
		894. (2000)		
	C37	Volkov, et al., "Methods for in Vitro DNA Recombination and Random Chimeragenesis",		
		Methods Enzymol., 328: 447-456 (2000)		
	C38	Wan, et al., "In vitro evolution of horse heart myoglobin to increase peroxidase activity", Proc.		
Ψ	1	Natl. Acad. Sci. USA, 95: 12825-12831 (1998)		

EXAMINER'S	Bubba Chemdum	DATE	3/28/05
SIGNATURE	JANOVE CHANNAMIN	CONSIDERED	1 0 (3

Complete if known

Application Number: 09/734,801

INFORMATION

TRANFARM

Filing Date: December 12, 2000

DISCLOSURE

First Named Inventor: Carlsson, et al.

STATEMENT

Group Art Unit: 1637

Examiner Name: Chunduru, Suryaprabha

SHEET 9 OF 9

Attorney Docket Number: 0046-P02386US0

Str.	C39	Zhao & Arnold, "Directed evolution converts subtilisin E into a functional equivalent of thermitase", Protein Eng., 12: 47-53, (1999)
800	C40	Zhao, et al., "Molecular evolution by staggered extension process (StEP) in vitro recombination", Nat. Biotechnol. 16: 258-261 (1998)

EXAMINER'S	Rubba Chemdiny	DATE	2/28/00
SIGNATURE	Bases Conscious	CONSIDERED	2(-3(-3)